• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Announces Upcoming Changes to Company's Board of Directors

    2/25/25 4:05:00 PM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email

    WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including: 

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    • Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025, pursuant to the mandatory director retirement age in the Company's Corporate Governance Guidelines;



    • President and CEO Ivan Tornos will become Chairman of the Board upon Mr. Begley's retirement; and



    • Michael Farrell will become Lead Independent Director upon Mr. Begley's retirement.

    Retirement of Mr. Begley

    "Chris has been a tremendous advisor to Zimmer Biomet since joining the Board in 2012. His vision, thoughtful counsel, and dedication to the Company have been instrumental in positioning Zimmer Biomet as a MedTech leader and innovator," said Mr. Tornos. "On behalf of the entire Board of Directors and Leadership Team, I want to extend my deep gratitude to Chris for his exemplary leadership and service as a member of Zimmer Biomet's Board. We have all benefited immensely from Chris's guidance, leadership and mentorship as Board Chair."

    Mr. Begley has been a member of the Company's Board of Directors since 2012, has served as Non-Executive Chairman since August 2023 and prior to that served as Lead Independent Director since May 2021. During his tenure as a Director, he has also served as a member of the Corporate Governance and the Compensation and Management Development Committees, and as Chair of the Quality, Regulatory and Technology Committee. He is the retired Chairman and Chief Executive Officer of Hospira, Inc. and the retired Non-Executive Chairman of the Board of Hanger, Inc. 

    Appointment of Mr. Tornos as Chairman of the Board 

    "Ivan has demonstrated bold leadership during his tenure as President and CEO, and prior to that as Chief Operating Officer, at Zimmer Biomet," said Mr. Begley. "I and the entire Board of Directors are excited to see how he continues to drive even stronger value for patients, shareholders, physicians and customers in his expanded role as Chairman of the Board." 

    Appointment of Mr. Farrell as Lead Independent Director 

    Mr. Farrell has been a Zimmer Biomet Board member since 2014 and currently serves as Chairman of the Compensation and Management Development Committee and as a member of the Quality, Regulatory and Technology Committee. He is the Chairman and Chief Executive Officer of ResMed Inc. Mr. Tornos stated, "We are honored to have Mick serve as our Lead Independent Director. He is a respected and accomplished business leader who brings strong integrity, a collaborative approach, and a valuable strategic perspective to our Board. I look forward to working with him in his new role." 

    About Zimmer Biomet

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.

    Cautionary Note Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this news release.

    Media

    Investors

    Heather Zoumas-Lubeski

    David DeMartino

    (445) 248-0577

    (646) 531-6115

    [email protected]

    [email protected]







    Zach Weiner



    (908) 591-6955



    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-upcoming-changes-to-companys-board-of-directors-302384933.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $ZBH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    1/4/2024$135.00 → $125.00Outperform → In-line
    Evercore ISI
    10/20/2023$120.00Neutral
    ROTH MKM
    More analyst ratings

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      11/13/23 4:02:02 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      9/29/23 4:05:41 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

      WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

      5/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

      WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

      3/6/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

      WARSAW, Ind., Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. Noor will be responsible for leading strategy development and execution and all facets of M&A, including the integration for our pending acquisition of Paragon 28. In addition, he will have oversight of the research and

      2/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/14/24 1:22:34 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

      SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/13/24 1:44:56 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      2/14/24 10:02:59 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    SEC Filings

    See more
    • Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

      8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      7/14/25 7:40:25 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement

      8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      6/30/25 4:15:36 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form S-8 filed by Zimmer Biomet Holdings Inc.

      S-8 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      6/20/25 4:32:27 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Thornal Kevin R

      3 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      7/7/25 4:15:32 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Group Pres, EMEA Van Zuilen Wilfred converted options into 2,631 shares and covered exercise/tax liability with 692 shares, increasing direct ownership by 10% to 21,473 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      7/3/25 4:10:43 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Higgins Arthur J

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      7/2/25 4:56:05 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zimmer Biomet upgraded by Roth Capital with a new price target

      Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00

      7/15/25 8:30:57 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet upgraded by Analyst with a new price target

      Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

      12/17/24 8:26:36 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Wolfe Research initiated coverage on Zimmer Biomet

      Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform

      9/10/24 8:03:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation o

      7/22/25 9:15:00 AM ET
      $AGEN
      $CLOV
      $MGRM
      $ZBH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Medical/Dental Instruments
    • Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

      Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs  Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas, July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ:MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per

      7/14/25 7:30:00 AM ET
      $MGRM
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results

      WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so

      7/9/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results

      WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so

      7/9/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025

      WARSAW, Ind., May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025. The cash dividend of $0.24 per share is payable on or about July 31, 2025 to stockholders of record as of the close of business on June 26, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamle

      5/30/25 7:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care